Overall rank by patents
#32,342
Across all tracked assignees
USPTO PatentsView assignee record - 8 granted patents across 2 technology areas, active 2022–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
The verdict
Laxxon holds 8 US patents across 2 technology areas, rank #32,342 of 50,000 tracked assignees.
Laxxon Medical Ag has been granted 8 US utility patents between 2022 and 2025, placing Laxxon Medical Ag at rank #32,342 across all assignees tracked by PlainPatent. This portfolio spans 2 distinct Cooperative Patent Classification (CPC) subclasses, averaging 26.5 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a Foreign Corporation, Laxxon Medical Ag is one of the more focused assignees in the PatentsView dataset. By volume, Laxxon sits between Lahey Clinic, Inc. (8 patents, rank #32,338) and Leapxpert Limited (8 patents, rank #32,346) - the closest US assignees by grant volume. The composite Innovation Score of 47.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2022 through 2025, with 8 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Laxxon Medical Ag's 26.5 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 2 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Laxxon Medical Ag against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Lahey Clinic, Inc.
8 patents
Laird Dabendorf GmbH
8 patents
Landmark Screens, LLC
8 patents
LanzaTech NZ, Inc.
8 patents
Lazurite Holdings LLC
8 patents
Le Commissariat à l'énergie atomique et aux énergies alternatives (CEA)
8 patents
LeapHigh Animals, LLC
8 patents
LeapXpert Limited
8 patents
Laxxon Medical AG
8 patents
What this shows Laxxon holds 8 patents at rank #32,342, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #32,342 in granted patent volume.
Other assignees with the most granted patents in Laxxon's primary technology class.
Laxxon's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
48 Top 18% higher than 82% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 2 | 25.0% |
| 2024 | 2 | 25.0% |
| 2025 | 4 | 50.0% |
Top 2 of 2 technology areas
Overall rank by patents
#32,342
Across all tracked assignees
47.6 out of 100
How to use this portfolio
Laxxon's 8 grants land it in the top 18% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.